首页 > 最新文献

Revista Espanola De Quimioterapia最新文献

英文 中文
[Macrolide-resistant Mycoplasma pneumoniae: Do we know the situation in Europe?] 耐大环内酯肺炎支原体:我们了解欧洲的情况吗?]
IF 1.9 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-06-01 DOI: 10.37201/req/118.2022
A I Álvaro Varela, A Aguinaga Pérez, A Navascués Ortega, J Castilla Catalán, C Ezpeleta Baquedano

Mycoplasma pneumoniae is a bacterium that lacks a cell wall. It produces infections all It produces infections world-wide, in epidemic outbreaks every 4-7 years, or endemically. Its clinical manifestations occur mostly in the respiratory tract and it is a common cause of atypical pneumonia. The treatment is with macrolides, tetracyclines or fluoroquinolones. Since 2000, an increase in resistance to macrolides has been detected worldwide, being more frequent in Asia. In Europe the frequency of resistance ranges between 1% and 25%, depending on the country. Molecular techniques and serology techniques provides very high sensitivity in diagnostic confirmation, being very useful for detecting and controlling M. pneumoniae outbreaks. The detection of resistance to macrolides requires a sequencing technique.

肺炎支原体是一种没有细胞壁的细菌。它在世界范围内产生感染,在每4-7年爆发一次的流行病中,或地方性地产生感染。其临床表现多见于呼吸道,是引起非典型肺炎的常见病因。治疗方法是大环内酯类、四环素类或氟喹诺酮类药物。自2000年以来,在世界范围内发现了对大环内酯类药物耐药性的增加,在亚洲更为常见。在欧洲,根据国家的不同,耐药性的频率在1%到25%之间。分子技术和血清学技术在诊断确认方面具有很高的灵敏度,对发现和控制肺炎支原体暴发非常有用。大环内酯类耐药的检测需要测序技术。
{"title":"[Macrolide-resistant Mycoplasma pneumoniae: Do we know the situation in Europe?]","authors":"A I Álvaro Varela,&nbsp;A Aguinaga Pérez,&nbsp;A Navascués Ortega,&nbsp;J Castilla Catalán,&nbsp;C Ezpeleta Baquedano","doi":"10.37201/req/118.2022","DOIUrl":"https://doi.org/10.37201/req/118.2022","url":null,"abstract":"<p><p>Mycoplasma pneumoniae is a bacterium that lacks a cell wall. It produces infections all It produces infections world-wide, in epidemic outbreaks every 4-7 years, or endemically. Its clinical manifestations occur mostly in the respiratory tract and it is a common cause of atypical pneumonia. The treatment is with macrolides, tetracyclines or fluoroquinolones. Since 2000, an increase in resistance to macrolides has been detected worldwide, being more frequent in Asia. In Europe the frequency of resistance ranges between 1% and 25%, depending on the country. Molecular techniques and serology techniques provides very high sensitivity in diagnostic confirmation, being very useful for detecting and controlling M. pneumoniae outbreaks. The detection of resistance to macrolides requires a sequencing technique.</p>","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/79/1a/revespquimioter-36-259.PMC10238793.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9570680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[First outbreak of Clostridioides difficile ribotype 027 in the Canary Islands]. [加那利群岛首次爆发艰难梭菌027型核糖型]。
IF 1.9 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-06-01 DOI: 10.37201/req/105.2022
M Aroca-Ferri, T Tosco-Núñez, M Peñate-Bolaños, J Molina-Cabrillana, M Ojeda-Vargas
{"title":"[First outbreak of Clostridioides difficile ribotype 027 in the Canary Islands].","authors":"M Aroca-Ferri,&nbsp;T Tosco-Núñez,&nbsp;M Peñate-Bolaños,&nbsp;J Molina-Cabrillana,&nbsp;M Ojeda-Vargas","doi":"10.37201/req/105.2022","DOIUrl":"https://doi.org/10.37201/req/105.2022","url":null,"abstract":"","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9f/d8/revespquimioter-36-317.PMC10238787.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9570642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Antibiotic resistance changes in episodes of symptomatic bacteriospermia: development in a health area of southeast Spain]. [症状性细菌精子症发作的抗生素耐药性变化:西班牙东南部一个卫生地区的发展]。
IF 1.9 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-06-01 DOI: 10.37201/req/117.2022
R Mendoza-Rodríguez, I Hernández-Chico, M Expósito-Ruiz, J M Navarro-Marí, J Gutiérrez-Fernández, A Rosales-Castillo

Objective: Chronic bacterial prostatitis (CBP) is an entity of difficult clinical diagnosis and treatment, being the microbiological study of semen the main diagnostic test. This study aimed to determine the etiology and antibiotic resistance in patients with symptomatic bacteriospermia (SBP) in our environment.

Methods: A cross-sectional and retrospective descriptive study has been carried out from a Regional Hospital of the Spanish Southeast. The participants were patients assisted in the consultations of the Hospital with clinic compatible with CBP, between 2016 and 2021. The interventions were collection and analysis of the results derived from the microbiological study of the semen sample. The main determinations were the etiology and rate of antibiotic resistance of BPS episodes are analyzed.

Results: The main isolated microorganism is Enterococcus faecalis (34.89%), followed by Ureaplasma spp. (13.74%) and Escherichia coli (10.98%). The rate of antibiotic resistance of E. faecalis to quinolones (11%) is lower than previous studies, while for E. coli it has been higher (35%). The low rate of resistance shown by E. faecalis and E. coli to fosfomycin and nitrofurantoin stands out.

Conclusions: In the SBP, gram-positive and atypical bacteria are established as the main causative agents of this entity. This forces us to rethink the therapeutic strategy used, which will avoid the increase in antibiotic resistance, recurrences, and chronicity of this pathology.

目的:慢性细菌性前列腺炎(CBP)是临床诊治困难的疾病,是精液微生物学研究的主要诊断手段。本研究旨在了解我国环境中症状性细菌精子症(SBP)患者的病因及耐药性。方法:横断面和回顾性描述性研究已从西班牙东南部地区医院进行。参与者是2016年至2021年期间在医院与CBP兼容的诊所进行会诊的患者。干预措施是收集和分析精液样本的微生物学研究结果。分析了BPS发作的病因和抗生素耐药率。结果:分离出的微生物以粪肠球菌为主(34.89%),其次为脲原体(13.74%)和大肠杆菌(10.98%)。粪肠杆菌对喹诺酮类抗生素的耐药率(11%)低于以前的研究,而大肠杆菌的耐药率则更高(35%)。粪肠杆菌和大肠杆菌对磷霉素和呋喃妥英的低耐药率尤为突出。结论:在收缩压中,革兰氏阳性和非典型细菌是该实体的主要病原体。这迫使我们重新思考所使用的治疗策略,这将避免抗生素耐药性的增加,复发和慢性病理。
{"title":"[Antibiotic resistance changes in episodes of symptomatic bacteriospermia: development in a health area of southeast Spain].","authors":"R Mendoza-Rodríguez,&nbsp;I Hernández-Chico,&nbsp;M Expósito-Ruiz,&nbsp;J M Navarro-Marí,&nbsp;J Gutiérrez-Fernández,&nbsp;A Rosales-Castillo","doi":"10.37201/req/117.2022","DOIUrl":"https://doi.org/10.37201/req/117.2022","url":null,"abstract":"<p><strong>Objective: </strong>Chronic bacterial prostatitis (CBP) is an entity of difficult clinical diagnosis and treatment, being the microbiological study of semen the main diagnostic test. This study aimed to determine the etiology and antibiotic resistance in patients with symptomatic bacteriospermia (SBP) in our environment.</p><p><strong>Methods: </strong>A cross-sectional and retrospective descriptive study has been carried out from a Regional Hospital of the Spanish Southeast. The participants were patients assisted in the consultations of the Hospital with clinic compatible with CBP, between 2016 and 2021. The interventions were collection and analysis of the results derived from the microbiological study of the semen sample. The main determinations were the etiology and rate of antibiotic resistance of BPS episodes are analyzed.</p><p><strong>Results: </strong>The main isolated microorganism is Enterococcus faecalis (34.89%), followed by Ureaplasma spp. (13.74%) and Escherichia coli (10.98%). The rate of antibiotic resistance of E. faecalis to quinolones (11%) is lower than previous studies, while for E. coli it has been higher (35%). The low rate of resistance shown by E. faecalis and E. coli to fosfomycin and nitrofurantoin stands out.</p><p><strong>Conclusions: </strong>In the SBP, gram-positive and atypical bacteria are established as the main causative agents of this entity. This forces us to rethink the therapeutic strategy used, which will avoid the increase in antibiotic resistance, recurrences, and chronicity of this pathology.</p>","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3b/71/revespquimioter-36-275.PMC10238802.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9623848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Status of Herpes Zoster and Herpes Zoster Vaccines in 2023: A position paper. 2023年带状疱疹和带状疱疹疫苗的现状:一份立场文件。
IF 1.9 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-06-01 DOI: 10.37201/req/004.2023
J M Molero García, S Moreno Guillén, F J Rodríguez-Artalejo, J Ruiz-Galiana, R Cantón, P De Lucas Ramos, A García-Botella, A García-Lledó, T Hernández-Sampelayo, J Gómez-Pavón, J González Del Castillo, M C Martín-Delgado, F J Martín Sánchez, M Martínez-Sellés, E Bouza

Herpes zoster infection (HZ) is an important public health problem due to its high incidence and frequent complications, especially post-herpetic neuropathy . The incidence of HZ increases with age and is more frequent in immunocompromised patients. It is estimated that at least 60,000 people develop HZ each year in Spain. The usual forms of HZ are so clinically characteristic that they do not usually require microbiological confirmation, which is reserved for cases without cutaneous manifestations or with atypical presentation. There are currently two vaccines approved by the regulatory agencies and marketed in Spain to prevent the onset of HZ and its complications. The first (Zostavax®) was marketed by the company MSD and licensed in Europe in 2006 and is a live attenuated virus vaccine that is administered in a single dose, while the second (Shingrix®) is a recombinant vaccine, marketed in 2017 and requires two doses. While the former cannot be administered to immunocompromised persons, the latter can be prescribed to any group of adults. The criteria for the indication and financing of these vaccines have not been uniform in the various autonomous communities of Spain. These and other aspects of HZ have been discussed by a group of experts from the Illustrious Official College of Physicians of Madrid (ICOMEM) whose criteria and opinions are included in this paper.

带状疱疹感染(HZ)发病率高,并发症多,特别是疱疹后神经病变,是一个重要的公共卫生问题。HZ的发病率随着年龄的增长而增加,在免疫功能低下的患者中更为常见。据估计,西班牙每年至少有6万人患上赫兹病。通常形式的HZ具有临床特征,通常不需要微生物学证实,这是为没有皮肤表现或不典型表现的病例保留的。目前有两种疫苗获得监管机构批准并在西班牙上市,以预防HZ及其并发症的发生。第一种(Zostavax®)由MSD公司于2006年在欧洲上市并获得许可,是一种单剂减毒活疫苗,而第二种(Shingrix®)是一种重组疫苗,于2017年上市,需要两剂。前者不能用于免疫功能低下的人,后者可用于任何成人群体。在西班牙各自治区,这些疫苗的适应症和筹资标准并不统一。马德里著名官方医师学院(ICOMEM)的一组专家对HZ的这些和其他方面进行了讨论,他们的标准和意见包括在本文中。
{"title":"Status of Herpes Zoster and Herpes Zoster Vaccines in 2023: A position paper.","authors":"J M Molero García,&nbsp;S Moreno Guillén,&nbsp;F J Rodríguez-Artalejo,&nbsp;J Ruiz-Galiana,&nbsp;R Cantón,&nbsp;P De Lucas Ramos,&nbsp;A García-Botella,&nbsp;A García-Lledó,&nbsp;T Hernández-Sampelayo,&nbsp;J Gómez-Pavón,&nbsp;J González Del Castillo,&nbsp;M C Martín-Delgado,&nbsp;F J Martín Sánchez,&nbsp;M Martínez-Sellés,&nbsp;E Bouza","doi":"10.37201/req/004.2023","DOIUrl":"https://doi.org/10.37201/req/004.2023","url":null,"abstract":"<p><p>Herpes zoster infection (HZ) is an important public health problem due to its high incidence and frequent complications, especially post-herpetic neuropathy . The incidence of HZ increases with age and is more frequent in immunocompromised patients. It is estimated that at least 60,000 people develop HZ each year in Spain. The usual forms of HZ are so clinically characteristic that they do not usually require microbiological confirmation, which is reserved for cases without cutaneous manifestations or with atypical presentation. There are currently two vaccines approved by the regulatory agencies and marketed in Spain to prevent the onset of HZ and its complications. The first (Zostavax®) was marketed by the company MSD and licensed in Europe in 2006 and is a live attenuated virus vaccine that is administered in a single dose, while the second (Shingrix®) is a recombinant vaccine, marketed in 2017 and requires two doses. While the former cannot be administered to immunocompromised persons, the latter can be prescribed to any group of adults. The criteria for the indication and financing of these vaccines have not been uniform in the various autonomous communities of Spain. These and other aspects of HZ have been discussed by a group of experts from the Illustrious Official College of Physicians of Madrid (ICOMEM) whose criteria and opinions are included in this paper.</p>","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/78/64/revespquimioter-36-223.PMC10238794.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9561760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Epidemiology and prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium in a tertiary hospital from Madrid, Spain. 西班牙马德里某三级医院生殖支原体大环内酯类药物和氟喹诺酮类药物耐药相关突变的流行病学和流行率
IF 1.9 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-06-01 DOI: 10.37201/req/123.2022
A Maldonado-Barrueco, M Rodríguez-Ayala, D Grandioso-Vas, P García-Clemente, G V Guedez-López, J García-Rodríguez, I Quiles-Melero

Objective: Mycoplasma genitalium causes persistent sexually transmitted infections. The aims of this study were to estimate the prevalence of resistances to macrolides and fluoroquinolones in M. genitalium and the sexually transmitted coinfections in patients at Hospital Universitario La Paz (Madrid, Spain).

Methods: Patients attended between January and October 2021 were studied. Screening for sexually transmitted pathogens and detection of 23S rRNA and parC genes mutations were performed by real-time PCR (Allplex,SeegeneTM).

Results: A total of 1,518 females and 1,136 males were studied. The prevalence of M. genitalium was 2.1%. The macrolides resistance rate was 51.8%. The mutations found were A2059G, A2058T and A2058G. The rate of resistance to fluoroquinolones was 17.8% being the G248T mutation (S83I) the most frequent. Seven males had some sexual transmitted coinfection.

Conclusions: Although the percentage of M. genitalium infections is low, the high rate of resistance to macrolides makes it necessary to revise the protocols for diagnosis and empirical treatment of sexually transmitted infections. The use of fluoroquinolones is appropriate after screening of macrolide resistance profile.

目的:生殖支原体引起持续性性传播感染。本研究的目的是估计拉巴斯大学医院(西班牙马德里)患者生殖支原体和性传播合并感染患者对大环内酯类药物和氟喹诺酮类药物耐药的流行情况。方法:对2021年1月至10月就诊的患者进行研究。采用实时荧光定量PCR技术(Allplex,SeegeneTM)筛选性传播病原体,检测23S rRNA和parC基因突变。结果:共研究了1518名女性和1136名男性。生殖支原体患病率为2.1%。大环内酯类药物耐药率为51.8%。发现的突变分别是A2059G、A2058T和A2058G。氟喹诺酮类药物耐药率为17.8%,以G248T突变(S83I)最为常见。7名男性有一些性传播合并感染。结论:虽然生殖支原体感染率较低,但对大环内酯类药物的高耐药率使得性传播感染的诊断和经验治疗方案有必要进行修订。筛选大环内酯类耐药概况后,适合使用氟喹诺酮类药物。
{"title":"Epidemiology and prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium in a tertiary hospital from Madrid, Spain.","authors":"A Maldonado-Barrueco,&nbsp;M Rodríguez-Ayala,&nbsp;D Grandioso-Vas,&nbsp;P García-Clemente,&nbsp;G V Guedez-López,&nbsp;J García-Rodríguez,&nbsp;I Quiles-Melero","doi":"10.37201/req/123.2022","DOIUrl":"https://doi.org/10.37201/req/123.2022","url":null,"abstract":"<p><strong>Objective: </strong>Mycoplasma genitalium causes persistent sexually transmitted infections. The aims of this study were to estimate the prevalence of resistances to macrolides and fluoroquinolones in M. genitalium and the sexually transmitted coinfections in patients at Hospital Universitario La Paz (Madrid, Spain).</p><p><strong>Methods: </strong>Patients attended between January and October 2021 were studied. Screening for sexually transmitted pathogens and detection of 23S rRNA and parC genes mutations were performed by real-time PCR (Allplex,SeegeneTM).</p><p><strong>Results: </strong>A total of 1,518 females and 1,136 males were studied. The prevalence of M. genitalium was 2.1%. The macrolides resistance rate was 51.8%. The mutations found were A2059G, A2058T and A2058G. The rate of resistance to fluoroquinolones was 17.8% being the G248T mutation (S83I) the most frequent. Seven males had some sexual transmitted coinfection.</p><p><strong>Conclusions: </strong>Although the percentage of M. genitalium infections is low, the high rate of resistance to macrolides makes it necessary to revise the protocols for diagnosis and empirical treatment of sexually transmitted infections. The use of fluoroquinolones is appropriate after screening of macrolide resistance profile.</p>","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f9/44/revespquimioter-36-310.PMC10238788.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9562247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clostridium perfringens abscess in parenteral drug users]. [肠外吸毒者的产气荚膜梭菌脓肿]。
IF 1.9 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-06-01 DOI: 10.37201/req/103.2022
A Maldonado-Barrueco, D Grandioso-Vas, J García-Rodríguez, I Quiles-Melero
{"title":"[Clostridium perfringens abscess in parenteral drug users].","authors":"A Maldonado-Barrueco,&nbsp;D Grandioso-Vas,&nbsp;J García-Rodríguez,&nbsp;I Quiles-Melero","doi":"10.37201/req/103.2022","DOIUrl":"https://doi.org/10.37201/req/103.2022","url":null,"abstract":"","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d3/2c/revespquimioter-36-314.PMC10238790.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9927906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to "The importance of an early gastroenteritis diagnosis to discard MIS-C during SARS-CoV-2 pandemic". 对“SARS-CoV-2大流行期间早期胃肠炎诊断对丢弃MIS-C的重要性”的回应。
IF 1.9 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-06-01 DOI: 10.37201/req/120.2022
P Rodríguez-Lorenzo, M Arias-Temprano, A Méndez-Sánchez, C Pérez-Méndez
Rev Esp Quimioter 2023;36(3): 322-324 322 Results are shown in Table 1. As expected, more cases of Campylobacter infection were diagnosed in the first period while more laboratory studies were performed in the second period (47.2% vs 14.9%), probably as a reflection of the fear of missing a possible diagnosis of MIS-C in the pandemic era. No cases showing both elevated C-reactive protein and profound lymphopenia were observed among the 74 children seen in the prepandemic period, while four (11.1% of the total cases and 30.6% of those in whom laboratory tests were performed) were found in the pandemic era. Evidence of SARS-CoV-2 exposure in the previous weeks was confirmed in three of these cases and infection was documented in one child, who was initially diagnosed as possible MIS-C and treated with intravenous gammaglobulin and corticosteroids for one day; treatment was suspended when the diagnosis of Campylobacter infection was confirmed. Clinical characteristics and laboratory findings of these four patients are shown in table 2. Our results raise the question of whether Campylobacter infection alone can be accountable for these laboratory findings and if a positive stool test can safely rule out a diagnosis of MIS-C or a short observation period in the hospital would be prudent, as children with MIS-C may develop additional organ system involvement over the course of admission [4]. Lymphopenia has been previously described in up to 11% of patients with Campylobacter infection returning from the tropics, Response to “The importance of an early gastroenteritis diagnosis to discard MIS-C during SARS-CoV-2 pandemic”
{"title":"Response to \"The importance of an early gastroenteritis diagnosis to discard MIS-C during SARS-CoV-2 pandemic\".","authors":"P Rodríguez-Lorenzo,&nbsp;M Arias-Temprano,&nbsp;A Méndez-Sánchez,&nbsp;C Pérez-Méndez","doi":"10.37201/req/120.2022","DOIUrl":"https://doi.org/10.37201/req/120.2022","url":null,"abstract":"Rev Esp Quimioter 2023;36(3): 322-324 322 Results are shown in Table 1. As expected, more cases of Campylobacter infection were diagnosed in the first period while more laboratory studies were performed in the second period (47.2% vs 14.9%), probably as a reflection of the fear of missing a possible diagnosis of MIS-C in the pandemic era. No cases showing both elevated C-reactive protein and profound lymphopenia were observed among the 74 children seen in the prepandemic period, while four (11.1% of the total cases and 30.6% of those in whom laboratory tests were performed) were found in the pandemic era. Evidence of SARS-CoV-2 exposure in the previous weeks was confirmed in three of these cases and infection was documented in one child, who was initially diagnosed as possible MIS-C and treated with intravenous gammaglobulin and corticosteroids for one day; treatment was suspended when the diagnosis of Campylobacter infection was confirmed. Clinical characteristics and laboratory findings of these four patients are shown in table 2. Our results raise the question of whether Campylobacter infection alone can be accountable for these laboratory findings and if a positive stool test can safely rule out a diagnosis of MIS-C or a short observation period in the hospital would be prudent, as children with MIS-C may develop additional organ system involvement over the course of admission [4]. Lymphopenia has been previously described in up to 11% of patients with Campylobacter infection returning from the tropics, Response to “The importance of an early gastroenteritis diagnosis to discard MIS-C during SARS-CoV-2 pandemic”","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fa/92/revespquimioter-36-322.PMC10238798.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9942696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bacteremia caused by Eikenella corrodens in a patient with pelvic inflammatory disease. 盆腔炎患者由艾肯氏菌引起的菌血症腐蚀。
IF 1.9 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-06-01 DOI: 10.37201/req/128.2022
M P Roche Matheus, D Fernández Vecilla, M J Urrutikoetxea Gutiérrez, F E Calvo Muro, G Iglesias Hidalgo, J L Díaz de Tuesta Del Arco
Rev Esp Quimioter 2023;36(3): 329-331 329 performed. During the surgery, adhesions of intestinal loops to the uterine fundus and bladder plica were found, as well as bilateral tuboovarian abscesses of approximately 7 cm each (the right one adhered to the posterior uterine face and the left one adhered to the Douglas pouch fundus. Intraoperatory samples were taken from one of the abscesses and sent to the microbiology laboratory for microbiological identification.
{"title":"Bacteremia caused by Eikenella corrodens in a patient with pelvic inflammatory disease.","authors":"M P Roche Matheus,&nbsp;D Fernández Vecilla,&nbsp;M J Urrutikoetxea Gutiérrez,&nbsp;F E Calvo Muro,&nbsp;G Iglesias Hidalgo,&nbsp;J L Díaz de Tuesta Del Arco","doi":"10.37201/req/128.2022","DOIUrl":"https://doi.org/10.37201/req/128.2022","url":null,"abstract":"Rev Esp Quimioter 2023;36(3): 329-331 329 performed. During the surgery, adhesions of intestinal loops to the uterine fundus and bladder plica were found, as well as bilateral tuboovarian abscesses of approximately 7 cm each (the right one adhered to the posterior uterine face and the left one adhered to the Douglas pouch fundus. Intraoperatory samples were taken from one of the abscesses and sent to the microbiology laboratory for microbiological identification.","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fb/11/revespquimioter-36-329.PMC10238795.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9574469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Shigellosis attended in the emergency department of a regional hospital in southeastern Spain: from their presence to multiresistance]. [志贺氏菌病在西班牙东南部一家地区医院的急诊科就诊:从其存在到多重耐药性]。
IF 1.9 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-06-01 DOI: 10.37201/req/121.2022
E Rodríguez-Guerrero, S Herrera-León, E Gómez-Vicente, J M Navarro-Marí, J Gutiérrez-Fernández

Objective: In the bacterial etiology of severe acute infectious diarrhea, except that caused by Clostridioides difficile, most of them have an invasive character and antibiotic treatment will be necessary in specific situations. Shigella is a classic pathogen, in which it is crucial to know the sensitivity to different classic and alternative antimicrobials. The objective of this work was to analyze the presence of shigellosis and the rate of antibiotic resistance.

Methods: A descriptive-retrospective study of the reports of shigellosis of stool cultures issued between January 2016 and April 2022 was conducted.

Results: A total of 34 episodes (16 -47.1%- by Shigella sonnei) were observed, as of 2018. There were only 2 pediatric cases. The overall resistance rate to azithromycin, trimethoprim-sulfamethoxazole and ciprofloxacin was 52.9%, 64.7% and 44.1%, respectively. 26.5% were resistant to the 3 groups of antibiotics. There was a higher rate of resistance for S. sonnei. The emergence of resistance to cephalosporins in recent years stands out. Episodes of multidrug-resistant shigellosis were detected between 2020 (1 by S. flexneri) and 2022 (4 by S. sonnei).

Conclusions: The episodes of shigellosis are emerging in our environment with a higher rate of multi-resistance. In this context, current empirical treatments for acute enteroinvasive enteritis are at risk of failure, if necessary.

目的:在严重急性感染性腹泻的细菌病因学中,除难辨梭状芽胞杆菌引起的腹泻外,其余均具有侵袭性,在特定情况下需要抗生素治疗。志贺氏菌是一种经典病原体,了解其对不同经典和替代抗菌素的敏感性至关重要。这项工作的目的是分析志贺氏菌病的存在和抗生素耐药率。方法:对2016年1月至2022年4月期间发布的粪便培养志贺氏菌病报告进行描述性回顾性研究。结果:截至2018年,共观察到34例(16例-47.1%)sonnei志贺氏菌。只有2例儿科病例。对阿奇霉素、甲氧苄啶-磺胺甲恶唑和环丙沙星的总耐药率分别为52.9%、64.7%和44.1%。26.5%的患者对3组抗生素耐药。sonnei的耐药率较高。近年来出现的对头孢菌素的耐药性尤为突出。在2020年(弗氏沙门氏菌1例)和2022年(索内沙门氏菌4例)之间发现了多重耐药志贺菌病。结论:志贺氏菌病在我国环境中不断出现,多重耐药率较高。在这种情况下,如果有必要,目前对急性肠侵入性肠炎的经验性治疗有失败的风险。
{"title":"[Shigellosis attended in the emergency department of a regional hospital in southeastern Spain: from their presence to multiresistance].","authors":"E Rodríguez-Guerrero,&nbsp;S Herrera-León,&nbsp;E Gómez-Vicente,&nbsp;J M Navarro-Marí,&nbsp;J Gutiérrez-Fernández","doi":"10.37201/req/121.2022","DOIUrl":"https://doi.org/10.37201/req/121.2022","url":null,"abstract":"<p><strong>Objective: </strong>In the bacterial etiology of severe acute infectious diarrhea, except that caused by Clostridioides difficile, most of them have an invasive character and antibiotic treatment will be necessary in specific situations. Shigella is a classic pathogen, in which it is crucial to know the sensitivity to different classic and alternative antimicrobials. The objective of this work was to analyze the presence of shigellosis and the rate of antibiotic resistance.</p><p><strong>Methods: </strong>A descriptive-retrospective study of the reports of shigellosis of stool cultures issued between January 2016 and April 2022 was conducted.</p><p><strong>Results: </strong>A total of 34 episodes (16 -47.1%- by Shigella sonnei) were observed, as of 2018. There were only 2 pediatric cases. The overall resistance rate to azithromycin, trimethoprim-sulfamethoxazole and ciprofloxacin was 52.9%, 64.7% and 44.1%, respectively. 26.5% were resistant to the 3 groups of antibiotics. There was a higher rate of resistance for S. sonnei. The emergence of resistance to cephalosporins in recent years stands out. Episodes of multidrug-resistant shigellosis were detected between 2020 (1 by S. flexneri) and 2022 (4 by S. sonnei).</p><p><strong>Conclusions: </strong>The episodes of shigellosis are emerging in our environment with a higher rate of multi-resistance. In this context, current empirical treatments for acute enteroinvasive enteritis are at risk of failure, if necessary.</p>","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/93/42/revespquimioter-36-282.PMC10238789.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9574470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Economic burden of skin and skin structure infections due to Gram-positive bacteria in patients on hospital at home-based outpatient parenteral antibiotic therapy (OPAT). 家庭门诊静脉注射抗生素治疗(OPAT)患者革兰氏阳性菌引起的皮肤和皮肤结构感染的经济负担
IF 1.9 4区 医学 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-06-01 DOI: 10.37201/req/134.2022
M Mirón-Rubio, J J Parra Jordán, V J González Ramallo, A Mujal Martínez, J Fernández Muixí, M Iglesias Gallego, M C Lucas Núñez, E Rodado Alabau, S Vidal Perez-Campoamor, E Uría

Objective: To describe and quantify resource use and direct health costs associated with skin and skin structure infections (SSSIs) caused by Gram-positive bacteria in adults receiving outpatient parenteral antimicrobial therapy (OPAT), administered by Hospital at Home units (HaH) in Spain.

Methods: Observational, multicenter, retrospective study. We included patients of both sexes included in the HaH-based OPAT Registry during 2011 to 2017 who were hospitalized due to SSSIs caused by Gram-positive bacteria. Resource use included home visits (nurses and physician), emergency room visits, conventional hospitalization stay, HaH stay and antibiotic treatment. Costs were quantified by multiplying the natural units of the resources by the corresponding unit cost. All costs were updated to 2019 euros.

Results: We included 194 episodes in 189 patients from 24 Spanish hospitals. The most frequent main diagnoses were cellulitis (26.8%) and surgical wound infection (24.2%), and 94% of episodes resulted in clinical improvement or cure after treatment. The median HaH stay was 13 days (interquartile range [IR]:8-22.7), and the conventional hospitalization stay was 5 days (IR: 1-10.7). The mean total cost attributable to the complete infectious process was €7,326 (95% confidence interval: €6,316-€8,416).

Conclusions: Our results suggest that OPAT administered by HaH is a safe and efficient alternative for the management of these infections and could lead to lower costs compared with hospital admission.

目的:描述和量化由西班牙家庭医院(HaH)管理的接受门诊肠外抗菌治疗(OPAT)的成人中革兰氏阳性菌引起的皮肤和皮肤结构感染(SSSIs)相关的资源使用和直接医疗成本。方法:观察性、多中心、回顾性研究。我们纳入了2011年至2017年期间因革兰氏阳性菌引起的sssi住院的ha -based OPAT登记处的男女患者。资源使用包括家访(护士和医生)、急诊室访问、常规住院、住院治疗和抗生素治疗。成本通过将资源的自然单位乘以相应的单位成本来量化。所有费用更新为2019欧元。结果:我们纳入了来自西班牙24家医院189名患者的194次发作。最常见的主要诊断为蜂窝织炎(26.8%)和手术伤口感染(24.2%),94%的发作经治疗后临床好转或治愈。中位住院时间为13天(四分位数间距[IR]:8-22.7),常规住院时间为5天(IR: 1-10.7)。整个感染过程的平均总成本为7326欧元(95%置信区间:6316 - 8416欧元)。结论:我们的研究结果表明,与住院相比,由ha管理的OPAT是一种安全有效的治疗这些感染的替代方法,并且可以降低成本。
{"title":"Economic burden of skin and skin structure infections due to Gram-positive bacteria in patients on hospital at home-based outpatient parenteral antibiotic therapy (OPAT).","authors":"M Mirón-Rubio,&nbsp;J J Parra Jordán,&nbsp;V J González Ramallo,&nbsp;A Mujal Martínez,&nbsp;J Fernández Muixí,&nbsp;M Iglesias Gallego,&nbsp;M C Lucas Núñez,&nbsp;E Rodado Alabau,&nbsp;S Vidal Perez-Campoamor,&nbsp;E Uría","doi":"10.37201/req/134.2022","DOIUrl":"https://doi.org/10.37201/req/134.2022","url":null,"abstract":"<p><strong>Objective: </strong>To describe and quantify resource use and direct health costs associated with skin and skin structure infections (SSSIs) caused by Gram-positive bacteria in adults receiving outpatient parenteral antimicrobial therapy (OPAT), administered by Hospital at Home units (HaH) in Spain.</p><p><strong>Methods: </strong>Observational, multicenter, retrospective study. We included patients of both sexes included in the HaH-based OPAT Registry during 2011 to 2017 who were hospitalized due to SSSIs caused by Gram-positive bacteria. Resource use included home visits (nurses and physician), emergency room visits, conventional hospitalization stay, HaH stay and antibiotic treatment. Costs were quantified by multiplying the natural units of the resources by the corresponding unit cost. All costs were updated to 2019 euros.</p><p><strong>Results: </strong>We included 194 episodes in 189 patients from 24 Spanish hospitals. The most frequent main diagnoses were cellulitis (26.8%) and surgical wound infection (24.2%), and 94% of episodes resulted in clinical improvement or cure after treatment. The median HaH stay was 13 days (interquartile range [IR]:8-22.7), and the conventional hospitalization stay was 5 days (IR: 1-10.7). The mean total cost attributable to the complete infectious process was €7,326 (95% confidence interval: €6,316-€8,416).</p><p><strong>Conclusions: </strong>Our results suggest that OPAT administered by HaH is a safe and efficient alternative for the management of these infections and could lead to lower costs compared with hospital admission.</p>","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/40/3d/revespquimioter-36-291.PMC10238797.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9574959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Revista Espanola De Quimioterapia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1